Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan.
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan.
Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):278-284. doi: 10.1016/j.hbpd.2019.03.010. Epub 2019 Apr 5.
Carbohydrate antigen 19-9 (CA19-9) is the most frequently used tumor marker and serves as a prognostic indicator in patients with pancreatic cancer (PC). The platelet-to-lymphocyte ratio (PLR) is thought to be an inflammation-related serum marker. An elevated PLR represents increased inflammatory status and is associated with poor prognosis in patients with various cancers including PC.
This study involved 103 patients with a histopathological diagnosis of pancreatic ductal adenocarcinoma who underwent pancreatectomy. The patients were assessed to determine the prognostic significance of the combination of the PLR and CA19-9 level.
Based on the receiver operating characteristic analysis results, the patients were divided into PLR (PLR ≥ 129.1) and PLR (PLR < 129.1) groups and into CA19-9 (CA19-9 ≥ 74.0 U/mL) and CA19-9 (CA19-9 < 74.0 U/mL) groups. The cumulative 5-year overall survival (OS) and disease-specific survival (DSS) rates significantly differed by both the PLR (PLR group: 19.5% and 22.9%; PLR group: 39.1% and 45.9%) and CA19-9 (CA19-9 group: 19.1% and 25.6%; CA19-9 group: 41.0% and 41.0%). We then divided the patients into Groups A (PLR/CA19-9), B (PLR/CA19-9 or PLR/CA19-9), and C (PLR/CA19-9). The cumulative 5-year OS rates in Groups A, B, and C were 44.0%, 31.9%, and 11.9%, respectively (P = 0.002). The cumulative 5-year DSS rates in Groups A, B, and C were 47.7%, 36.4%, and 16.8%, respectively (P = 0.002). Multivariate analysis revealed that the combination of the PLR and CA19-9 was an independent prognostic factor in patients with resected PC.
The combination of the PLR and CA19-9 is useful for predicting the prognosis of patients with resected PC.
糖类抗原 19-9（CA19-9）是最常用的肿瘤标志物，可作为胰腺癌（PC）患者的预后指标。血小板与淋巴细胞比值（PLR）被认为是一种与炎症相关的血清标志物。升高的 PLR 代表炎症状态增加，与包括 PC 在内的各种癌症患者的不良预后相关。
本研究纳入了 103 例经组织病理学诊断为胰腺导管腺癌并接受胰腺切除术的患者。评估患者的预后，以确定 PLR 与 CA19-9 水平联合的预后意义。
根据受试者工作特征分析结果，将患者分为 PLR（PLR≥129.1）和 PLR（PLR＜129.1）组以及 CA19-9（CA19-9≥74.0 U/mL）和 CA19-9（CA19-9＜74.0 U/mL）组。PLR（PLR 组：19.5%和 22.9%；PLR 组：39.1%和 45.9%）和 CA19-9（CA19-9 组：19.1%和 25.6%；CA19-9 组：41.0%和 41.0%）两组患者的 5 年累积总生存率（OS）和疾病特异性生存率（DSS）差异均有统计学意义。随后，我们将患者分为 A 组（PLR/CA19-9）、B 组（PLR/CA19-9 或 PLR/CA19-9）和 C 组（PLR/CA19-9）。A、B 和 C 组患者的 5 年累积 OS 率分别为 44.0%、31.9%和 11.9%（P=0.002）。A、B 和 C 组患者的 5 年累积 DSS 率分别为 47.7%、36.4%和 16.8%（P=0.002）。多因素分析显示，PLR 和 CA19-9 联合是可切除 PC 患者的独立预后因素。
PLR 和 CA19-9 的联合可用于预测可切除 PC 患者的预后。
